Rion

Our RION team recently participated in a blood drive in Rochester, MN, where team members came together to donate blood. Blood donations play a crucial role in supporting community health, providing essential transfusions for those in need, from accident victims to patients undergoing surgeries or battling illness.   We are grateful to all the donors who participated and encourage everyone to consider donating to their local blood bank. Together, we can make a difference.

Dr. Maureen Merrifield, Rion's Chief Regulatory Officer will be hosting a Precision Medicine Forum Short Course: Regulatory Pathways for the Translation EV Therapeutics from Pre-Clinical Research to the Clinic.

Great addition to Rion's leadership team #exosome #regenerative medicine #biologics

We are proud to announce that RION has expanded its leadership team with the appointment of five renowned experts—James B. Peake, M.D., Raquel C. Bono, M.D., Steven L. Moran, M.D., Andrew Omidvar, Ph.D., and Steve Reed, Ph.D.—to our Advisory Board.   These distinguished leaders bring decades of expertise across orthopedic and plastic surgery, infectious diseases, military medicine, biomanufacturing, and government health strategy, further strengthening RION’s position as a pioneer in exosome-based therapeutics. Their exceptional contributions will be instrumental in advancing our groundbreaking platform technology and bringing transformative regenerative therapies to patients worldwide.   Follow us for more exciting updates as we continue to revolutionize regenerative medicine through innovative leadership and scientific excellence. https://lnkd.in/gh-e8PV8

We are proud to announce that RION attended the Military Health System Research Symposium (MHSRS) to present our innovative approach for the treatment of severe burns and wounds with our breakthrough platelet-derived exosome technology.    As the Department of Defense’s premier scientific meeting, MHSRS brings together experts from across the military medical community, regulatory agencies, and industry to develop solutions for unmet needs in military medicine. RION’s presence at this symposium reflects our commitment to advancing medical solutions through cutting-edge exosome technology, designed to promote tissue regeneration and improve outcomes in severe injury care.    Follow us for more exciting updates and breakthroughs as we continue to change and revolutionize the approach to regenerative medicine.

We are pleased to announce that Jahan Jowharchi, Chief Technical Operations, will be one of the key speakers at the world-renowned 6th Annual Exosome-Based Therapeutic Development Summit in Boston, MA from September 17-19, 2024. This conference brings together industry leaders to accelerate exosome based therapeutic development with advanced pre-clinical models, scalable manufacturing, and clinical success. Jahan will highlight RION’s leadership in exosome innovation and our proprietary manufacturing process, and supply chain which enables the large-scale production of regenerative exosomes. With our cutting-edge technology, RION is helping to shape the future of regenerative medicine by ensuring clinical and therapeutic success through scalable manufacturing. Follow us for more exciting updates as we continue to revolutionize the approach to exosome-based therapies.

We are thrilled to announce the initiation of our Phase 1b clinical trial evaluating Purified Exosome Product™ (PEP™) for knee osteoarthritis, a groundbreaking step in the field of regenerative medicine. As the first FDA-approved study to evaluate therapeutic exosomes in orthopedics, this trial represents a pivotal moment for both RION and the future of knee osteoarthritis treatment.   The trial will involve 24 patients across the U.S. in a randomized, open-label study, focusing on the safety and early efficacy of PEP™ for Knee OA. Patients will receive single intra-articular injections of PEP™, aimed at providing relief to the 364 million people affected globally by this debilitating condition.   At RION, our mission is to transform patient care through innovative exosome technology. Built on decades of research, our proprietary PEP™ platform is designed to address the unmet needs of chronic conditions like Knee OA.   Learn more about this groundbreaking trial and the potential of our PEP™ technology by clicking the link below. https://lnkd.in/ecgNTcd7

We are thrilled to announce the initiation of our Phase 1b clinical trial evaluating Purified Exosome Product™ (PEP™) for knee osteoarthritis, a groundbreaking step in the field of regenerative medicine. As the first FDA-approved study to evaluate therapeutic exosomes in orthopedics, this trial represents a pivotal moment for both RION and the future of knee osteoarthritis treatment.   The trial will involve 24 patients across the U.S. in a randomized, open-label study, focusing on the safety and early efficacy of PEP™ for Knee OA. Patients will receive single intra-articular injections of PEP™, aimed at providing relief to the 364 million people affected globally by this debilitating condition.   At RION, our mission is to transform patient care through innovative exosome technology. Built on decades of research, our proprietary PEP™ platform is designed to address the unmet needs of chronic conditions like Knee OA.   Learn more about this groundbreaking trial and the potential of our PEP™ technology by clicking the link below. https://lnkd.in/ecgNTcd7

We are hiring a Sr. Scientist, Quality Control. This is a unique opportunity to work at a leading clinical-stage regenerative medicine company at the forefront of exosome innovation. Apply now using the link below and become a pivotal part of RION's mission to innovate and transform patient care. https://lnkd.in/eBNwFtrb #JobOpening #BiotechCareers #RION #RochesterMNJobs #JoinOurTeam

Excited to share this case report of PEP curing a non-healing radiation wound. Tremendous testament of Dr. Van Able's dedication to her patients and the Rion team's work to provide PEP exosomes for this clinical effort.